Japan’s Kyorin Pharmaceutical has entered into a global license agreement with Swiss pharma giant Novartis relating to ...

Kyorin Pharmaceutical Co. Ltd. has out-licensed its preclinical candidate, KRP-M223, and its back-up compounds to Novartis Pharma AG in a deal worth up to $777.5 million. Under the terms, Novartis ...

Novartis is further bolstering its preclinical pipeline and continuing its hunt for a Xolair successor, nailing down a ...

The U.K has released a huge repository of children’s genomic data after sequencing blood samples from three large cohorts recruited at birth and followed across three decades. The power of the data is ...

On Wednesday, Teladoc Health reported that its 2024 revenue dropped 1% to $2.57 billion. The company projected a revenue ...

Ice cream for breakfast? Why not? Here's what makes ice cream a good breakfast addition, and ways to pair those frozen scoops ...

“The data clearly showed that the frequency and duration of physical restraint and seclusion are overwhelmingly high in Japan,” said Toshio Hasegawa, a professor of psychiatry at Kyorin ...

Kyorin Pharma has signed a deal with Hyfe to develop a digital therapeutic (DTx) for people with chronic cough and launch it in Japan.

Kyorin Pharma has signed a deal with Hyfe to develop a digital therapeutic (DTx) for people with chronic cough and launch it in Japan.

M223, a preclinical drug for inflammatory diseases, with potential milestone payments of $777.5M plus royalties.